黄芪注射液对H22荷瘤小鼠抗肿瘤作用机制  

An experimental study on anti -tumor effects of Astragalus injection on H22 cell-bearing mice

作　　者：黄云峰[1] 李连琨[1] 谢旱红 陈果[1] 周青春[1] 王滨容[1] 

机构地区：[1]武警四川总队成都医院,610041

出　　处：《武警医学》2011年第7期562-564,共3页Medical Journal of the Chinese People's Armed Police Force

摘　　要：目的研究黄芪注射液对H22荷瘤小鼠的抗肝脏肿瘤作用,并初步探讨其作用机制。方法应用H22荷瘤小鼠模型进行体内抗肿瘤试验,绘制肿瘤生长曲线并计算抑瘤率;免疫组化方法检测肿瘤组织的微血管密度(microvessel density,MVD)。结果在12 g/kg、8g/kg和4 g/kg的剂量下黄芪注射液的抑瘤率分别为51.6%、33.06%和17.81%。免疫组化结果表明,黄芪注射液具有显著的抑制肿瘤血管生成的作用,且呈现剂量依赖关系。结论黄芪注射液具有较强的体内抗肝脏肿瘤作用,其机制可能与抑制肿瘤血管生成有关。Objective To study the anti - tumor effect of astragalus injection on H22 cell - bearing mice. Methods A mouse hepatic cancer H22 model was developed to study the anti - hepatocarcinoma activity of astragalus injection in vivo. The growth curve and inhibitory rate of tumor growth were measured. MVD was analyzed by irnmunohistochemistry. Results Under the treatment of 12, 8, 4 g/kg of astragalus injection, the inhibitory rate of H22 transplanted tumor in mice was 51.6% , 33.06%, and 17.81% , respectively, lmmunohistochemical assay showed that the vascular density of H22 transplanted tumor in astragalus injection was lower than in the control group. Conclusions Astragalus injection has significant anti - tumor effects in vivo. The mechanism may be related to strong inhibitory etfects on angiogenesis.

关 键 词：黄芪注射液 肝癌 H22荷瘤小鼠 

分 类 号：R73-361[医药卫生—肿瘤]